Imaging Studies in Corticobasal Syndrome

Launched by JENNIFER WHITWELL · May 23, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a condition called corticobasal syndrome (CBS), which affects movement and can cause various symptoms like stiffness and trouble with coordination. The main goal of the study is to look at how inflammation and damage in the brain's white matter are related to CBS. Researchers will use advanced imaging techniques and blood tests to gather information that could help improve understanding and treatment of the condition.

To participate in this study, individuals must be over 18 years old and show specific symptoms associated with CBS, such as difficulty with movement or coordination. However, those who have certain medical conditions or take specific medications may not be eligible. Participants will undergo scans and tests to help researchers gather important data about CBS. It's important to note that women who can become pregnant will need to have a negative pregnancy test before undergoing specific scans. This study is currently recruiting participants, and it offers a chance to contribute to valuable research that may help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Meet possible or probable CBS criteria
• Exclusion Criteria:
• • Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)
• • Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome
• • Subjects will be excluded if they have a mutation in the progranulin gene
• • Subjects will excluded if they have received anti-Aβ therapy
• • Women who are pregnant will be excluded
• • Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)
• • Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning